Wednesday, April 11, 2007 :: Imaging Diagnostic Systems Changes China Distribution Approach
Imaging Diagnostic Systems Changes China Distribution Approach

Fort Lauderdale, Florida, April 11, 2007—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast imaging systems, announced that it has modified its China distribution arrangements to accelerate market penetration of the new CT Laser Mammography system (CTLM®).

IDSI terminated its exclusive agreement with China Far East International Trading Corp. (CFET) to permit IDSI to appoint non-exclusive distributors and representatives in the country. Tim Hansen, IDSI Chief Executive Officer, recently met with CFET representatives in Beijing to work out the details. He also visited breast imaging specialists in Beijing, Tianjin, Guangzhou, Hong Kong, and Macau to discuss how CTLM might improve their practices.

Hansen explained the change in distribution: “We had a nice start with CFET some time ago. We earned the Chinese government’s SFDA approval for the CTLM, sold several systems, and installed a CTLM at the Beijing Friendship Hospital to qualify for procedure payments under the Beijing health care system. We subsequently were approved for procedure payments.

“In July 2006, with the encouragement of CFET and BAC, the company we hired to manage our Asian distributors, IDSI opened a representative office in Beijing and added marketing, administrative, and service support personnel. We wanted to show that we were taking the market opportunity seriously and providing the very best customer service and support. Despite these moves, sales have not met our expectations. In fact, the lack of sales in China has been a huge disappointment and we believe one of the causes may have been lack of market coverage and CTLM clinical awareness. Our new approach will allow us to appoint distributors in multiple areas and work directly with luminaries and health care organizations. With our office and staff now in place, we believe we are positioned to support CFET customers as well as new distributors.

“The good news is that the breast cancer detection and treatment market in China is enormous,” continued Hansen, “and our technology can play a vital role in delivering better and more effective breast cancer management tools to patients and clinicians. We must seize this opportunity.”

The CTLM system is a new continuous wave laser breast imaging system that utilizes state-of-the-art technology and patented algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to radiation or require breast compression. In the United States, Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The Imaging Diagnostic Systems CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Tuesday, April 10, 2007 :: CT Laser Mammography Study Cites Importance of Assessing Breast Angiogenesis in Cancer Cases
CT Laser Mammography Study Cites Importance of Assessing Breast Angiogenesis in Cancer Cases

Study Published in the Egyptian Journal of Radiology and Nuclear Medicine


Fort Lauderdale, Florida, April 10, 2007—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), a pioneer in laser optical breast imaging systems, announced the publication of a significant medical study, “Role of CTLM in Early Detection of Vascular Breast Lesions.” The paper, by Mohammed Emad E. Eid, M.D., Ph.D., et al., was published in The Egyptian Journal of Radiology and Nuclear Medicine, Vol. 37, No. 1, (March): 633-643, 2006.

The study highlighted the importance of imaging the presence and extent of angiogenesis in breasts as a means to improve breast cancer detection and management methods. Angiogenesis is the formation of new blood vessels. In the breast, such new vessels are associated with cancer growth.

According to Tim Hansen, IDSI Chief Executive Officer, “Dr. Emad’s work, conducted on 450 breasts, cites the problems with conventional breast imaging techniques and emphasizes the important role our new CT Laser Mammography system (CTLM®) can play in improving detection and management. The only other technique to image neovascularization is MRI; CTLM is less invasive, less expensive, and may have sensitivity advantages.”

The CTLM procedures were performed by Dr. Emad in the Department of Radiology, SAQR Hospital, RAK, United Arab Emirates.

In the United States, Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The Imaging Diagnostic Systems CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Wednesday, March 7, 2007 :: Imaging Diagnostic Systems Research Scientist Presents Results on New Imaging Technique
Imaging Diagnostic Systems Research Scientist Presents Results on New Imaging Technique


Fort Lauderdale, Florida, March 7, 2007—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast imaging systems, announced that Sergey Telenkov, Ph.D., IDSI Research Scientist, presented an abstract, “Fourier-Domain Methodology for Depth-Selective Photothermoacoustic Imaging of Tissue Chromophores,” at the 14th International Conference on Photoacoustic and Photothermal Phenomena in Cairo, Egypt, January 6 - 9, 2007.

Telenkov presented results from a collaborative effort with the University of Toronto, through which a novel imaging modality was developed: a hybrid technology referred to as photothermoacoustic (PTA) imaging. Biomedical applications of PTA methodology have been pursued by numerous research groups over the past decade because of the potentially high-resolution functional imaging capabilities that could result, significantly exceeding those available to purely optical modalities. The team’s results demonstrated the attractive features of the FD-PTA technique including high signal-to-noise ratio, depth-selective imaging and excellent axial resolution without high peak-power nanosecond laser exposure.

“My primary research objective as a member of the R&D group at IDSI is the reliable detection of breast cancer. CTLM technology clearly demonstrates the potential to help solve this important problem. However, hybrid techniques such as photothermoacoustic imaging may provide additional advancements to the current imaging modality, especially in terms of spatial resolution,” Telenkov explained.

Telenkov’s results on FD-PTA imaging will be also presented at the March 2007 meeting of the American Physical Society in Denver, Colorado.

The CTLM system is a new continuous wave laser breast imaging system that utilizes state-of-the-art technology and patented algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to radiation or require breast compression. In the United States, Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The Imaging Diagnostic Systems CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Tuesday, January 30, 2007 :: Imaging Diagnostic Systems Updates Patent Scorecard
Imaging Diagnostic Systems Updates Patent Scorecard


Fort Lauderdale, Florida, January 30, 2007 - Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), a pioneer in laser optical breast imaging systems, announced the issuance of U.S. Patent 7,155,274, entitled “Optical Computed Tomography Scanner for Small Laboratory Animals,” its 17th US patent in the optical CT field.

“This patent covers the key claims of our Laser Imager for Laboratory Animals (LILA), and is the cornerstone of the intellectual property being exclusively licensed to Bioscan, Inc., a Washington, DC, company that intends to commercialize the technology. Specifically, this patent protects the concepts of a helical optical CT scanner optimized for simultaneously imaging attenuation and fluorescence in small laboratory animals,” stated Robert Wake, IDSI’s VP of Engineering.

IDSI also noted that, since a previous release on US patents issued in 2004, 9 international patents have issued to IDSI, more than doubling IDSI’s international patent portfolio to 15 and its total portfolio to 32 patents. “Our main business is human breast optical imaging with CTLM systems, where we command a leadership position, as evidenced by our global portfolio,” commented Wake.

Recent international patents include:

Australian patent 775069, issued July 2004; European patent EP01181511, issued June 2005; Hong Kong patent HK1043480, issued January 2006; and German patent DE69925869 issued May 2006; all entitled “Laser Imaging Apparatus Using Biomedical Markers That Bind to Cancer Cells”. These 4 patents, along with a previously issued Canadian patent, are equivalents of US patent 5,952,644 and protect the concept of imaging and activating a photodynamic therapy agent in an optical CT scanner, a combined diagnostic and therapeutic system.

European patent EP01005286, issued July 2004, and Hong Kong patent HK1029508, issued December 2004, both entitled “Method for Reconstructing the Image of an Object Scanned with a Laser Imaging Apparatus,” are equivalents of US patent 6,130,958. These 2 patents protect the image reconstruction algorithms employed in CTLM technologies.

Hong Kong patent HK1029506, issued December 2004, entitled “Device for Determining the Contour of the Surface of an Object Being Scanned,” is equivalent to US patent 6,044,288. It, along with a previously issued European patent, protects the perimeter-measurement technique employed in the CTLM, which is essential to reconstructing optical CT images.

Chinese patent ZL01809326.4, entitled “Multiple Wavelength Simultaneous Data Acquisition Device for Breast Imaging,” issued in November 2005. This patent, equivalent to US patent 6,571,116, protects the concept of multiple wavelength optical data acquisition in an optical CT scanner for the purpose of tissue characterization.

European patent EP01389441, issued May 2006, entitled “Diagnostic Tomographic Laser Imaging Apparatus.” This patent, equivalent to US patent 5,692,511, protects the basic CTLM optical CT concept.

The CTLM system is a new continuous wave laser breast imaging system that utilizes state-of-the-art technology and patented algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to radiation or require breast compression. In the United States, Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The Imaging Diagnostic Systems CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com